Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene
08-Jan-2024 -
Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
Through this collaboration, ...
cancer
drug development
drug discovery
+4